UK Medical Cannabis Market Update 2026: Growth, Pricing, & Regulation
UK Medical Cannabis Market Update 2026: Growth, Pricing, & Regulation
The landscape of prescribed medical cannabis in the United Kingdom has undergone rapid development since the initial scheduling changes in November 2018. Over the past several years, the sector has transitioned from a small, highly restricted group of patients to a rapidly growing healthcare segment.
According to the latest industry reports and clinical registries, the UK has become one of the fastest-growing medical cannabis markets in Europe. This update provides a factual, data-driven analysis of patient numbers, import statistics, product pricing trends, and regulatory changes in 2026.
Surge in Patient Numbers and Import Volumes
The UK medical cannabis market relies entirely on imported products, as domestic commercial cultivation of high-THC cannabis flower remains highly restricted.
Recent figures compiled by industry analysts at Prohibition Partners highlight a significant expansion in supply chains and patient access:
- Patient Growth: The number of active patients prescribed medical cannabis in the UK is projected to reach 140,000 by the end of 2026, up from approximately 100,000 just a year earlier.
- Import Statistics: During 2025, a total of 30,061 kilograms of medical cannabis were imported into the UK. This represents more than double the 14,992 kilograms imported in 2024.
- Supply Origins: Canada is now the primary exporter, supplying between 70% and 80% of all medical cannabis entering the UK (including shipments routed through Portugal). Other historic suppliers, such as Spain, have seen their market share adjust to approximately 11%.
Product Diversity and Pricing Reductions
With the growth of patient numbers, competition between international cultivators and importers has intensified. This has led to a wider variety of prescribed formulations and a reduction in average costs for patients.
- Product Range: The number of cannabis-based medicines (CBPMs) officially imported and available to UK patients doubled over the past year, leaping from 374 to 818 distinct products. This includes flower, sublingual oils, vape cartridges, and oral solutions.
- Average Costs: The average price of medical cannabis flower—the format most widely prescribed by specialists—declined from £7.10 per gram to £6.80 per gram over the past year.
- Vaporiser Cartridge Pricing: The average cost of pre-filled vape cartridges fell by approximately 25%, making inhalation options more accessible for patients who require immediate symptom relief.
Regulatory and Clinical Governance
Despite the growth in size, access to medical cannabis in the UK operates almost entirely within the private sector. The National Health Service (NHS) issues very few prescriptions for unlicensed cannabis medicines, primarily due to strict clinical guidelines from the National Institute for Health and Care Excellence (NICE).
As a result, patients access care through a network of private online teleclinics. This concentrated model has drawn closer attention from healthcare regulators:
- Care Quality Commission (CQC): The CQC is responsible for registering and inspecting private clinics in England. The regulator has increased its audit oversight to ensure that clinics maintain proper clinical governance, perform comprehensive initial assessments, and do not compromise patient safety for rapid onboarding.
- Advisory Council on the Misuse of Drugs (ACMD): The ACMD is currently conducting a formal review of the availability, prescribing practices, and safety of CBPMs in the UK. The council’s findings are expected to shape future regulations and potentially establish standardized clinical training requirements for prescribers.
- Specialist Prescribing Rules: Under current regulations, medical cannabis can only be initiated by a specialist doctor listed on the GMC Specialist Register who is prescribing within their area of expertise (e.g., a neurologist for epilepsy, or a pain specialist for chronic pain). General Practitioners (GPs) cannot initiate CBPM prescriptions, though they may participate in shared-care monitoring.
Patient Safety and Pharmacovigilance
As patient numbers rise, monitoring side effects and maintaining strict safety records is critical. Under UK guidelines, all private clinics must participate in active pharmacovigilance.
Patients who experience adverse side effects from prescribed cannabis-based products are urged to report them to the MHRA Yellow Card Scheme. Yellow Card reports allow the Medicines and Healthcare products Regulatory Agency to track safety signals across the entire patient population.
Market Statistics Summary (2024 vs. 2025/2026)
| Metric | 2024 | 2025 / 2026 (Projected) | Trend |
|---|---|---|---|
| Active Patients | ~100,000 | 140,000 | +40% |
| Annual Imports | 14,992 kg | 30,061 kg | +100% |
| Available Products | 374 | 818 | +118% |
| Avg. Flower Price | £7.10/g | £6.80/g | -4.2% |
| Primary Exporter | Spain/Canada | Canada (70-80%) | Shift to Canada |
Disclaimer: MCRx is an independent information directory, not a clinical provider or distributor. Market data is compiled from published industry analysis. Medical cannabis remains a controlled drug. Always seek advice from a registered specialist doctor regarding treatment options.